SETH LEDERMAN - 23 Feb 2023 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Executive Officer, Director
Signature
/s/ Seth Lederman
Issuer symbol
TNXP
Transactions as of
23 Feb 2023
Transactions value $
$0
Form type
4
Filing time
24 Feb 2023, 17:34:28 UTC
Previous filing
01 Jul 2022
Next filing
29 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +700,000 $0 700,000 23 Feb 2023 Common Stock 700,000 $0.731 Direct F1, F2
transaction TNXP Stock Option Award $0 +700,000 $0 700,000 23 Feb 2023 Common Stock 700,000 $0.914 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F2 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.